Peptide Knowledge Base · Metabolic
Metformin: what it is, what the evidence says, and its real status
A first-line diabetes drug, not a peptide, widely studied as a longevity and metabolic agent.
Short version: not a peptide, the most-prescribed metabolic drug in the world, studied for longevity (the TAME trial). By request and supervised.
Can you actually get it?
Plain-English verdict: Waitlist.
Regulatory status: By request · SKU request.
By request, clinician-supervised. Metformin is an FDA-approved diabetes medicine studied off-label for metabolic and longevity benefit (the TAME trial). It is a related longevity compound, not a peptide.
How does Metformin work?
Reduces hepatic glucose output and improves insulin sensitivity; proposed to influence aging-related pathways including AMPK.
What it does — and what it does not do
What it does: Improves insulin sensitivity and glycemic control; studied for metabolic and longevity benefit.
What it does not do: Longevity benefit in non-diabetics is not yet proven, and it is not a peptide.
How honest is the evidence?
Evidence grade B — decades of human metabolic data; longevity case under formal trial (TAME). Read our grading methodology for what each grade means.
What we still don't know: Whether it extends healthspan in metabolically healthy people is the open question TAME aims to answer.
WADA status: Not prohibited.
How it is taken
Clinician-set; oral. Educational only.
Who should not take it
Caution with significant kidney impairment; GI tolerability common early. Clinician-supervised.
Sources
Metformin metabolic literature · TAME trial (Barzilai et al.)
Compounded medications are not FDA-approved. We keep two signals separate and never collapse them: whether you can get something, and what the rule currently says. See the live FDA Peptide Tracker or the knowledge base.
Last reviewed 2026-08-11 · Peptós.LIFE · Not medical advice.